Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saroglitazar in liver transplant recipients with NAFLD
NCT03639623Phase 2Completed
- Sponsor
- Zydus Therapeutics
- Start
- Feb 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of saroglitazar in non-alcoholic fatty liver disease (NAFLD), sponsored by Zydus Therapeutics. Started Feb 2019; status: completed.
02
Drugs
saroglitazar
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03639623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639623.